| Name | Title | Contact Details |
|---|---|---|
Alan Smith |
Chief Technology Officer | Profile |
Alto Neuroscience is redefining psychiatry by developing personalized and highly effective medicines to help patients get better faster. Our artificial intelligence (AI)-enabled platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.
Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
Incept BioSystems is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enzon Pharmaceuticals Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.